Incyte Corporation

INCY

US45337C1027

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 07:30 pm IST

More Strategies

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.66 USD

Average target price

72.62 USD

Spread / Average Target

+25.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.17%	12.97B
CSL LIMITED	+3.79%	95.71B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.64B
BIOGEN INC.	-13.20%	32.7B
UCB	+79.53%	28.65B
BIOMARIN PHARMACEUTICAL INC.	-16.02%	15.38B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.35%	11.47B
ALTEOGEN INC.	+160.91%	9.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-56.29%	9.07B
SWEDISH ORPHAN BIOVITRUM AB	+3.30%	8.84B

Biopharmaceuticals

Delayed Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
57.66 ^USD	-2.30%		-6.62%	-8.17%

02/07	S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments	MT
02/07	S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments	MT

S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments	03/07	MT
S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments	03/07	MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	02/07	MT
Incyte Shares Fall Following BMO Capital Downgrade	02/07	MT
You can't escape politics	02/07
BMO Capital Downgrades Incyte to Underperform From Market Perform, Adjusts Price Target to $48 From $52	02/07	MT
ANALYST RECOMMENDATIONS : Adobe, Nike, Solaredge, Welltower, Spectris...	02/07
Incyte Insider Sold Shares Worth $1,149,840, According to a Recent SEC Filing	14/06	MT
Incyte Reports Tender Offer Results	13/06	MT
Tranche Update on Incyte Corporation's Equity Buyback Plan announced on May 13, 2024.	13/06	CI
Incyte Reports Preliminary Tender Offer Results	11/06	MT
Transcript : Incyte Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM	10/06
Incyte Corporation's Equity Buyback announced on May 13, 2024, has closed with 27,866,666 shares, representing 12.41% for $1,672 million.	10/06	CI
Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	23/05	MT
Incyte Acquires 2 Office Buildings in Delaware	21/05	MT
Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM	15/05
Equities Close Mixed as Markets Weigh Consumer Inflation Survey	14/05	MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey	14/05	MT
Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey	13/05	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	13/05	MT
Increasing Short-Term Inflation Expectations Weigh on US Equity Indexes Ahead of Consumer, Producer Prices	13/05	MT
US Equity Indexes Trade Mixed as Short-Term Inflation Expectations Increase	13/05	MT
Incyte Corporation announces an Equity Buyback for $1,672 million worth of its shares.	13/05	CI
Sector Update: Health Care Stocks Decline Pre-Bell Monday	13/05	MT
Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares	13/05	MT